The North American Menopause Society Statement on Continuing Use of Systemic Hormone Therapy After Age 65

Menopause

Volumn 22, Issue 7, 2015, Pages 693-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE;

AGE; AGED; CLINICAL DECISION MAKING; DRUG CONTRAINDICATION; DRUG EFFICACY; FEMALE; HEALTH HAZARD; HORMONAL THERAPY; HUMAN; MEDICAL SOCIETY; MENOPAUSE; PATIENT DECISION MAKING; SHORT SURVEY; CONTRAINDICATIONS; DRUG EFFECTS; ESTROGEN THERAPY; PRACTICE GUIDELINE; QUALITY OF LIFE; RISK ASSESSMENT; UNITED STATES; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; QUALITY OF LIFE; RISK ASSESSMENT; UNITED STATES;

EID: 84937040825     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000492     Document Type: Short Survey

References (5)

1. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257-271.
2. Avis NE, Crawford SL, Greendale G, et al Study of Women's Health Across the Nation (SWAN). Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015;175:531-539.
3. Gartoulla P, Worsley R, Bell RJ, Davis SR. Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years. Menopause 2015;22:694-701.
4. Kaunitz AM. Extended duration use of menopausal hormone therapy. Menopause 2014;21:679-681.
5. ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol 2014;123:202-216.